HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a price target of $33.
March 08, 2024 | 6:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals maintains a Buy rating from HC Wainwright & Co. with a $33 price target.
The reaffirmation of a Buy rating and a significant price target of $33 by HC Wainwright & Co. suggests a strong confidence in EyePoint Pharmaceuticals' future performance. This endorsement from a reputable analyst firm could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100